Syros Pharmaceuticals enters into a clinical supply agreement with Janssen (JNJ)
Janssen will supply daratumumab for a recently added combination dosing cohort in Syros' ongoing Phase 2 clinical trial of SY-1425, a first-in-class selective retinoic acid receptor alpha (RARa) agonist, in genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
- In exchange for providing daratumumab, Janssen will receive access to data from the cohort evaluating the safety and efficacy of SY-1425 in combination with daratumumab for its research and development programs related to daratumumab.
- The study will continue to be sponsored solely by Syros. Enrollment in the combination cohort with azacitidine began last year and is ongoing.
- Syros expects to begin enrolling patients in the combination cohort with daratumumab in early 2018.
- Syros expects to present initial clinical data on both combinations in 2018.